tbuckley/cabot-search huggingface dataset:
AB0352 The Changing Face of Septic Arthritis Complicating Rheumatoid Arthritis in The Era of Biotherapies. Retrospective Single-Center Study over 35 Years
Authors: J.-J. Dubost, B. Pereira, A. Tournadre, Z. Tatar, M. Couderc, M. Soubrier
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is a risk factor for septic arthritis (SA), and anti-TNF therapy doubles the risk of SA. <h3>Objectives</h3> The purpose of this study was to see whether the frequency and features of SA complicating RA have changed over the last 35 years. <h3>Methods</h3> This retrospective single-center study included the full register of all patients hospitalized at the rheumatology department of Clermont-Ferrand – CHU between 1979 and 2013 for septic arthritis bacteriologically documented by synovial fluid and/or blood culture samples. The periods 1979–2002 (period before biotherapies) and 2003–2013 (last decade in the era of biotherapies) were compared. <h3>Results</h3> Between 1979 and 2013, 64/514 (12.5%) SA presented with a RA – 21/153 (13.7%) in the 2003–2013 period and 43/361 (11.9%) in the 1979–2002 period. Over the past decade, median age of SA–RA patients increased (61 <i>vs</i> 68 years; <i>p</i>&lt;0.02) and predominant gender became males (52% <i>vs</i> 40%). The features of the RA remained unchanged: history (18 years (8–29) <i>vs</i> 16 (8–25)), rheumatoid factor (95% <i>vs</i> 87%), and corticosteroids (91% <i>vs</i> 81%) at the same mean dose (10 mg/d). 71% in the period before biotherapies and 63% in the last decade received a DMARD. Over the last decade 24% (<i>vs</i> 0; <i>p</i>&lt;0.003) of patients received a biologic DMARD: etanercept (n=2), adalimumab (n=1), rituximab (n=1), tocilizumab (n=1). Proportion of polyarticular infection had decreased (9.5% <i>vs</i> 37%; <i>p</i>&lt;0.02), down to the same level as SA-non-RA cases (8%). Proportion of <i>S. aureus</i> infections had stabilized (62% <i>vs</i> 74%) in SA-RA patients but was higher than SA-non-RA (47% and 53%). MRSA infections became more frequent in SA-RA (31% <i>vs</i> 6%; <i>p</i>&lt;0.05) in contrast to SA-non-RA cases (8% <i>vs</i> 16%; ns). Gram-negative bacilli infections have tended to become more frequent (19% <i>vs</i> 5%; <i>p</i>=0.08). Blood cultures less often tested positive (29% <i>vs</i> 47%; ns). Mortality rates has fallen slightly (5% <i>vs</i> 9%; ns), in contrast to SA-non-RA cases (7% <i>vs</i> 6%; ns). <h3>Conclusions</h3> This study brings reassuring findings – in the era of biotherapies, the frequency of septic arthritis complicating rheumatoid arthritis has stabilized, and the most severe septic polyarticular forms are on the decline. <h3>Disclosure of Interest</h3> None declared
Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs “Discontinuous” Remission (Rd): Results of Total Therapies 1 &amp; 2 (TT1,2) for Multiple Myeloma (MM).
Authors: Bart Barlogie, Erik Rasmussen, Guido Tricot, Teresa Milner, Elias Anaissie, Frits van Rhee, John Shaughnessy, Joshua Epstein, Klaus Hollmig, Maurizio Zangari, John Crowley
Journal: Blood (2005)
Cell Therapy: In Vitro Topographical Model of Fuchs Dystrophy for Evaluation of Corneal Endothelial Cell Monolayer Formation (Adv. Healthcare Mater. 22/2016)
Authors: Muhammad Rizwan, Gary S. Peh, Khadijah Adnan, Sacha L. Naso, Alon R. Mendez, Jodhbir S. Mehta, Evelyn K. F. Yim
Journal: Advanced Healthcare Materials (2016)

Micro-structural changes in the corneal endothelial basement membrane cause Fuchs dystrophy, which leads to corneal blindness. On page 2896, Muhammad Rizwan and co-workers demonstrate a micro-fabricated in vitro disease model of Fuchs dystrophy by recapitulating the topographical details of diseased basement membrane. This model is employed to elucidate complex interaction of corneal cells with the disease-like surface to study corneal endothelial monolayer reformation for the development of corneal cell regenerative therapies.
Rejection of Primary Lymphoma Cells Derived from c-myc-Transgenic Mice after Haploidentical Transplantation: Treatment of the Tumor May Confer to Resistance Against GvL-Effect.
Authors: Madhusudhanan Sukumar, Andrea Wilke, Josef Mautner, Hans-Jochem Kolb, Georg Bornkamm, Armin Gerbitz
Journal: Blood (2005)
PTH-063 Dietary Advice in an Inflammatory Bowel Disease Clinic – Are We Offering What Patients Want?
Authors: E Peck, K Blair, N Reynolds, C Mowat, M Groome, E Robinson
Journal: Gut (2016)

<h3>Introduction</h3> Inflammatory Bowel Disease (IBD) is a lifelong condition; predominantly diagnosed in young adults, adolescents and children it can also commonly involve malnutrition. The IBD Service Standards suggest all patients should have access to dietary advice, during hospital stays and in out-patients, whether in relapse or remission. We wanted to assess the nature and demand for dietary advice within a cohort of out-patients. <h3>Methods</h3> Over a three week period, consecutive patients attending the IBD clinic in a Teaching Hospital were given an anonymised questionnaire. The questionnaire covered individual demographics, history of their condition, whether they had received dietary advice and from whom. Additionally, we asked for their preferred format of dietary advice. This data was analysed according to the relationships between these categories. <h3>Results</h3> A total of 136 questionnaires were completed. 80 (59%) were completed by females, aged 20–86 years, and 56 (41%) by males, aged 17–82 years. 78 patients indicated they had Crohn’s Disease (CD) (M:F 32:46) and 54 Ulcerative Colitis (UC) (M:F 24:30); 7 marked the field as “unknown”. 76% of all patients would like a dietary resource but only 50.7% had received advice previously (58% of patients with CD, and 41% with UC). 50% of those diagnosed in the past year, and 50% who were not, had received dietary advice. The majority of dietary advice was given by a dietician (43%), then a doctor (28%), then friends or from personal research (16%) and finally, IBD nurses gave dietary advice 9% of the time. In 4% the source of advice was unknown. Of those wanting dietary advice the most popular formats were written (35%) followed by no preference and online (both 29%), then electronic (7%). The majority (54%) stated that if a resource was available, they would not need to see a dietician. <h3>Conclusion</h3> Half of the patients in this cohort have received no dietary advice despite there being a clear demand for it. Additionally, this figure has not improved in the past year. The majority of patients with CD have had formal dietetic advice and this has mainly been delivered by dieticians, which is appropriate. There remains however a high demand within patients with IBD to receive dietary advice. Patients would be happy to receive advice through an accessible resource rather than see a dietician face to face; this should be available to allow limited dietetic time to be focussed on those patients with a specific need. A written, widely available resource proves to be the best format for this. <h3>Disclosure of Interest</h3> None Declared
AB0388 Risk of Non Adherence To Oral Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. ARCO Study:
Authors: I. Monteagudo, E. Raya Alvarez, C. Marras Fernandez-Cid, G. Salvador Alarcόn, T.R. Vázquez-Rodríguez, J.V. Tovar Beltrán, A. Escudero-Contreras, J.J. Alegre-Sancho, A.M. Ortiz García, A. Olivé, L. Cea-Calvo, M.J. Arteaga, Y. Mestre, J. Calvo-Alén
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Lack of adherence to medication in rheumatoid arthritis (RA) can worsen disease activity. <h3>Objectives</h3> To evaluate the risk of non-adherence to disease modifying antirheumatic drugs (DMARD) in RA patients treated with subcutaneous (SC) biological therapy. <h3>Methods</h3> ARCO was a retrospective study in RA patients ≥18 years-old from 42 Spanish hospitals on SC biological therapy. The risk of non-adherence to oral DMARD was evaluated using the Compliance Questionnaire in Rheumatology (CQR), a questionnaire validated against an electronic medication-monitoring system, for a cut-off point of taking ≤80% of the doses. Patients completed the Beliefs About Medicines Questionnaire (BMQ) and the Carbonell satisfaction questionnaire (Spanish validated questionnaire on satisfaction with medication). <h3>Results</h3> 364 patients were included (mean age 54.9 years [SD 12.5]; 77.5% women median RA duration 7.8 years). Complete CQR was available for 304 patients, of which 21.7% showed risk of non-adherence to oral DMARD (95% CI: 17.4 – 26.7%). The percentage was similar in men and women, and greater in extremes of age (&gt;63 and ≤48 years-old), in those currently working and in patients with no comorbidities (Table). There was a trend to a higher percentage at risk of non-adherence in non-Caucasian patients, those with higher educational level and in those with risk of alcoholism (AUDIT questionnaire) (Table). The percentage with risk of non-adherence was similar in patients with 1, 2 or &gt;2 oral drugs for RA, and in those treated or not with SC methotrexate, and it was higher in those who considered that the effect of their treatment for RA on the symptoms had been less than expected (38.1% vs 17.9% in those who thought it had been greater, p=0.029). No differences were seen with regard to the result of the BMQ. <h3>Conclusions</h3> In patients with RA treated with SC biological therapy, 21.7% showed risk of non-adherence to DMARD according to the CQR (taking ≤80% of the doses). The percentage was higher in extremes of age, patients with university degree, employed, without comorbidities and in those who considered that the treatment effect on RA had been lower than expected. <h3>Acknowledgement</h3> The ARCO study was funded by Merck Sharp &amp; Dohme Spain. <h3>Disclosure of Interest</h3> None declared
Demographics, Treatment Patterns, Safety, and Real-World Effectiveness in Patients ≥70 Years of Age with Chronic Lymphocytic Leukemia Receiving Bendamustine with or without Rituximab,
Authors: Kathryn S. Kolibaba, Avani D. Joshi, James A. Sterchele, Michael Forsyth, Erin Alwon, Hooman Beygi, Gerard T. Kennealey
Journal: Blood (2011)
Erratum: Corrigendum: Identification of a role for TRIM29 in the control of innate immunity in the respiratory tract
Authors: Junji Xing, Leiyun Weng, Bin Yuan, Zhuo Wang, Li Jia, Rui Jin, Hongbo Lu, Xian Chang Li, Yong-Jun Liu, Zhiqiang Zhang
Journal: Nature Immunology (2016)
Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium
Authors: Yoshihiro Inamoto, Xiaoyu Chai, Brenda Kurland, Daniel J. Weisdorf, Paul J. Martin, David Jacobsohn, Joseph Pidala, Jeanne Palmer, Sally Arai, Corey Cutler, Madan Jagasia, Mary E.D. Flowers, Mukta Arora, Steven Z. Pavletic, Georgia B. Vogelsang, Stephanie J. Lee, Paul A. Carpenter
Journal: Blood (2012)
OP12NEW TOOLS TO STUDY HISTONE H3.3 MUTATIONS IN DIPG AND PHGG
Authors: Farhana Haque, Aikaterini Bountali, Ruman Rahman, Robert Layfield, Richard Grundy
Journal: Neuro-Oncology (2015)

INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) is an aggressive malignant astrocytoma in children, with poor survival rate and few treatment options. Recently, K27M somatic mutations have been identified in histone H3.1 and H3.3 proteins in 80% of DIPGs and 20% of non-brain stem paediatric gliomas. In addition, 30% of paediatric high grade gliomas (pHGG) exhibit G34R or G34V H3.3 mutations. Several studies have highlighted the epigenetic changes associated with these mutations, however their precise role in tumourigenesis is still unknown. METHOD: We have generated novel polyclonal antibodies that can discriminate H3.3 G34R and G34V mutant proteins from their wild-type counterparts. The antibodies were validated by western blot, immunofluorescence and immunohistochemistry. RESULTS: The antibodies exhibit specific reactivity against recombinant H3.3 proteins, transfected mammalian cells, DIPG and pHGG H3.3 mutant cell lines, and patient samples. CONCLUSION: These antibodies can now be used to study the consequences of single amino acid substitutions in H3.3, for example by providing insights into spatial/anatomical aspects of the mutations in DIPG. They may find prognostic utility in the rapid identification of H3.3 mutant DIPG/pHGG cases and will be used to identify novel downstream targets and pathways of the different mutants in DIPG/pHGG genesis and progression.
Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.
Authors: Eldad J. Dann, Rachel Bar-Shalom, Ada Tamir, Nissim Haim, Irit Avivi, Diana Gaitini, Menachem Ben-Shachar, Ora Israel, Jacob M. Rowe, Ron Epelbaum
Journal: Blood (2006)
THU0581 Risk of Malignancy among Patients with Sarcoidosis: A Population-Based Cohort Study
Authors: P. Ungprasert, C.S. Crowson, E.L. Matteson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Previous studies on the association between sarcoidosis and malignancy yielded conflicting results. <h3>Objectives</h3> This study was aimed to investigate the risk of malignancy in patients with sarcoidosis in a population-based cohort. <h3>Methods</h3> An inception cohort of patients with incident sarcoidosis in 1976–2013 in a geographically well-defined population was identified based on comprehensive individual medical record review. Inclusion required physician diagnosis supported by histopathologic evidence of non-caseating granuloma, radiographic evidence of intrathoracic sarcoidosis, compatible clinical presentation, and exclusion of other granulomatous diseases. For each sarcoidosis subject, two sex and aged-matched comparator subjects without sarcoidosis were randomly selected. Cases and comparators were then cross-indexed with the Cancer Registry of the institution, which collected data on every type of malignancy except for non-melanoma skin cancer, for malignancy ascertainment. <h3>Results</h3> 345 incident cases of sarcoidosis and 690 comparators were identified. The median duration of follow-up was 12 years. There was no difference in the prevalence of malignancy at sarcoidosis incidence/index date between the 2 groups (14 cases, 3.8% among cases and 30 cases, 4.3% among comparators, <i>P</i>=0.87) compared to non-sarcoidosis subjects. During follow-up, 37 patients with sarcoidosis and 91 subjects without sarcoidosis developed malignancy with a cumulative incidence at 10 years of 4.1% and 7.1%, respectively. The difference corresponded to a hazard ratio of 0.74 (95% confidence interval (CI), 0.50 -1.09). The cumulative incidences at 10 years for individual types of malignancy were also similar between patients with sarcoidosis and non –sarcoidosis comparators, with non-significant hazard ratios. However, subgroup analysis found that cases with extra-thoracic involvement were at higher risk of incident hematologic malignancy compared with cases without extra-thoracic involvement (HR 1.87; 95% CI 1.09–3.22) <h3>Conclusions</h3> Risk of malignancy was similar among patients with sarcoidosis compared to non-sarcoidosis subjects. However, the risk of incident hematologic malignancy was significantly higher among patients with sarcoidosis with extra-thoracic involvement compared to patients without extra-thoracic disease. <h3>Disclosure of Interest</h3> None declared
Patient and health-care provider perspectives of pregnancy-related health-care provision in Guangdong, China: a qualitative interview-based study
Authors: Shanshan Xiong, Sihui Luo, Xueying Zheng, Chaofan Wang, Jinhua Yan, Yan Guo, Yanhua Zhu, Daizhi Yang, Liling Qiu, Bin Yao, Jianping Weng
Journal: The Lancet Diabetes & Endocrinology (2016)
Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL.
Authors: Stefan Faderl, Kanti R. Rai, John Gribben, Ian Flinn, John C. Byrd, David McConkey, David Schenkein, Dixie Esseltine, Mary L. Browning, Michael J. Keating
Journal: Blood (2004)
Identification of AML and MDS Patients Who Could Potentially Benefit From Temozolomide Therapy: Proportion of Patients with Low Methyl Guanine Methyltransferase (MGMT) Expression Level
Authors: Joseph Brandwein, Jeannine Kassis, Brian Leber, Kang Howson-Jan, Mark D. Minden, Kim Greaves, Jean-Francois Pouliot
Journal: Blood (2010)
Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I
Authors: Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Sue Erickson-Viitanen, William Sun, Victor A. Sandor, Hagop M. Kantarjian
Journal: Blood (2011)
SAT0471 Osteoarthritis Is Related To Cardiovascular Disease and Increased Arterial Stiffness. A Case-Control Study: Table 1
Authors: S.A. Provan, S. Rollefstad, I.J. Berg, I.B. Wilkinson, C.M. McEniery, A.G. Semb, T.K. Kvien, N. Østerås, I.K. Haugen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Osteoarthritis (OA) is associated with an increased risk of CVD<sup>1</sup>, but confounder bias has not been sufficiently explored in observational studies. Pulse wave velocity (PWV) and augmentation index (AIx) are predictors of future CVD events. <h3>Objectives</h3> To investigate the relationship between OA and CVD, PWV and AIx, accounting for confounders. <h3>Methods</h3> All residents of Ullensaker municipality, aged between 40 and 79 years were mailed a questionnaire concerning general health and musculoskeletal pain (Musculoskeletal pain in Ullensaker Study (MUST)). Respondents who reported having OA were invited to an extended clinical examination at Diakonhjemmet Hospital, Oslo, Norway. OA was diagnosed according to the ACR clinical classification criteria. Demographics and co-morbidities were recorded on questionnaires. AIx and PWV were measured (Sphygmocor apparatus, Atcor®). Participants in the Oslo control cohort were recruited by Statistics Norway, and underwent a similar data-collection (response rate 41%). Data from the Anglo-Cardiff Collaborative Trial (ACCT), a community based population study (response rate 85%) from the United Kingdom, formed a secondary control population. In separate logistical regression models, adjusted for age, sex, we compared the odds ratio (OR) for CVD and elevated AIx and PWV (dichotomized at median) between participants in MUST, ACCT controls and Oslo controls. Patients with hand OA were compared against patients with lower limb OA (hip and/or knee OA). AIx was adjusted for heart rate and height, whereas PWV was adjusted for heart rate. A confounder was defined as a variable which changed the estimate of the exposure effect by ≥20% when entered into the model. <h3>Results</h3> Out of 583 patients in MUST with self-reported OA, 153 (26.2%) had isolated hand OA according to the ACR criteria and 153 (26.2%) had lower limb OA. 134 persons consented to participate in the Oslo control cohort. 1111 patients without inflammatory joint disorders from the ACCT were randomly selected as controls. The age and sex adjusted logistical regression models are presented in the table. Analyses with additional adjustment for smoking, BMI, CRP, anti-hypertensive and statin treatment, respectively, gave similar results. <h3>Conclusions</h3> Patients with OA have an increased frequency of CVD, and higher levels of AIx and PWV, compared to ACCT controls. Lower limb OA seems to be associated with CVD to a greater extent than hand OA. No confounder variables were identified in these analyses. <h3>References</h3> Nuesch BMJ. 2011;342:d1165. <h3>Disclosure of Interest</h3> None declared
The common mouse protozoa<i>Tritrichomonas muris</i>alters mucosal T cell homeostasis and colitis susceptibility
Authors: Nichole K. Escalante, Paul Lemire, Mayra Cruz Tleugabulova, David Prescott, Arthur Mortha, Catherine J. Streutker, Stephen E. Girardin, Dana J. Philpott, Thierry Mallevaey
Journal: The Journal of Experimental Medicine (2016)

The mammalian gastrointestinal tract hosts a diverse community of microbes including bacteria, fungi, protozoa, helminths, and viruses. Through coevolution, mammals and these microbes have developed a symbiosis that is sustained through the host’s continuous sensing of microbial factors and the generation of a tolerant or pro-inflammatory response. While analyzing T cell–driven colitis in nonlittermate mouse strains, we serendipitously identified that a nongenetic transmissible factor dramatically increased disease susceptibility. We identified the protozoan Tritrichomonas muris as the disease-exacerbating element. Furthermore, experimental colonization with T. muris induced an elevated Th1 response in the cecum of naive wild-type mice and accelerated colitis in Rag1−/− mice after T cell transfer. Overall, we describe a novel cross-kingdom interaction within the murine gut that alters immune cell homeostasis and disease susceptibility. This example of unpredicted microbial priming of the immune response highlights the importance of studying trans-kingdom interactions and serves as a stark reminder of the importance of using littermate controls in all mouse research.
Myeloid Dysfunction in Sickle Cell Disease
Authors: Alessandra Romano, Nunziatina Laura Parrinello, Concetta Conticello, Rossellina Rosso, Perrotta Caterina, Grazia Colletta, Benedetta Ximenes, Piera La Cava, Carmela RITA Meli, Francesco Di Raimondo
Journal: Blood (2014)
Abstract 20758: Chemotherapy Treatment Increases the Risk of Developing Atrial Fibrillation in Breast Cancer
Authors: Brandon Chalazan, Rob Lentz, Mark McCauley, Matt Kolek, Eric Farber-Eger, Quinn Wells, Javid Moslehi, Dawood Darbar
Journal: Circulation (2016)

Introduction: With an aging population and increasing cancer survivors, radiotherapy and chemotherapy mediated cardiovascular disease is becoming more prevalent. However, little is currently known ...